Early Deregulation of Cholangiocyte NR0B2 During Primary Sclerosing Cholangitis

Overview

Journal Gastro Hep Adv

Specialty Gastroenterology

Date 2024 Aug 12

PMID 39130146

Authors

Christophe Desterke

Chuhan Chung

David Pan

Michael Trauner

Didier Samuel

Daniel Azoulay

Cyrille Feray

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Primary sclerosing cholangitis (PSC) is a probable autoimmune liver disease characterized by persistent and progressive biliary inflammation that leads to biliary infection, cirrhosis, or cholangiocarcinoma. Genome-wide omics data are scarce regarding this severe disease.

Methods: MEDLINE database gene prioritization by text mining (biliary inflammation, biliary fibrosis, biliary stasis) was integrated in distinct omics data: (1) PSC liver transcriptome training and validation cohorts, (2) farnesoid X receptor (FXR) mice liver transcriptome subjected to an FXR agonist or FXR knockout mice; (3) liver single-cell transcriptome of the Abcb4-/- mice model of PSC.

Results: A liver molecular network highlighted the involvement of nuclear receptor subfamily 0 group B member 2 (NR0B2) and its associated nuclear receptor FXR in a metabolic cascade that may influence the immune response. NR0B2 upregulation in PSC liver was independent of gender, age, body mass index, liver fibrosis, and PSC complications. Heterogeneity of NR0B2 upregulation was found in cholangiocyte cell types in which the NR0B2-based cell fate decision revealed the involvement of several metabolic pathways for detoxification (sulfur, glutathione derivative, and monocarboxylic acid metabolisms). Genes potentially implicated in carcinogenesis were also discovered on this cholangiocyte trajectory: GSTA3, inhibitor of DNA binding 2, and above all, TMEM45A, a transmembrane molecule from the Golgi apparatus considered as oncogenic in several cancers.

Conclusion: By revisiting PSC through PubMed data mining, we evidenced the early cholangiocyte deregulation of NR0B2, highlighting a metabolic and premalignant reprogramming of the cholangiocyte cell type. The therapeutic targeting of NR0B2 could potentiate that of FXR and enable action on early events of the disease and prevent its progression.

References

Ruhlemann M, Liwinski T, Heinsen F, Bang C, Zenouzi R, Kummen M . Consistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis. Aliment Pharmacol Ther. 2019; 50(5):580-589. PMC: 6899739. DOI: 10.1111/apt.15375. View

Mertz A, Nguyen N, Katsanos K, Kwok R . Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: an update of the evidence. Ann Gastroenterol. 2019; 32(2):124-133. PMC: 6394256. DOI: 10.20524/aog.2019.0344. View

Gronemeyer H, Gustafsson J, Laudet V . Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov. 2004; 3(11):950-64. DOI: 10.1038/nrd1551. View

Zhan L, Liu H, Fang Y, Kong B, He Y, Zhong X . Genome-wide binding and transcriptome analysis of human farnesoid X receptor in primary human hepatocytes. PLoS One. 2014; 9(9):e105930. PMC: 4157742. DOI: 10.1371/journal.pone.0105930. View

JOHANSSON A, Mannervik B . Human glutathione transferase A3-3, a highly efficient catalyst of double-bond isomerization in the biosynthetic pathway of steroid hormones. J Biol Chem. 2001; 276(35):33061-5. DOI: 10.1074/jbc.M104539200. View

Butler A, Hoffman P, Smibert P, Papalexi E, Satija R . Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol. 2018; 36(5):411-420. PMC: 6700744. DOI: 10.1038/nbt.4096. View

Trapnell C, Cacchiarelli D, Grimsby J, Pokharel P, Li S, Morse M . The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat Biotechnol. 2014; 32(4):381-386. PMC: 4122333. DOI: 10.1038/nbt.2859. View

Benezra R, Davis R, Lockshon D, Turner D, Weintraub H . The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell. 1990; 61(1):49-59. DOI: 10.1016/0092-8674(90)90214-y. View

Oude Elferink R, Paulusma C . Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). Pflugers Arch. 2006; 453(5):601-10. DOI: 10.1007/s00424-006-0062-9. View

10.

Harder J, Muller M, Fuchs M, Gumpp V, Schmitt-Graeff A, Fischer R . Inhibitor of differentiation proteins do not influence prognosis of biliary tract cancer. World J Gastroenterol. 2014; 19(48):9334-42. PMC: 3882406. DOI: 10.3748/wjg.v19.i48.9334. View

11.

Tahboub Amawi A, Tremaine W, Venkatesh S . Pembrolizumab-Induced Sclerosing Cholangitis. Clin Gastroenterol Hepatol. 2020; 20(2):e18. DOI: 10.1016/j.cgh.2020.11.048. View

12.

Pavlidis P, Noble W . Analysis of strain and regional variation in gene expression in mouse brain. Genome Biol. 2001; 2(10):RESEARCH0042. PMC: 57797. DOI: 10.1186/gb-2001-2-10-research0042. View

13.

Horvath S, Erhart W, Brosch M, Ammerpohl O, von Schonfels W, Ahrens M . Obesity accelerates epigenetic aging of human liver. Proc Natl Acad Sci U S A. 2014; 111(43):15538-43. PMC: 4217403. DOI: 10.1073/pnas.1412759111. View

14.

Lee S, Stewart S, Nagtegaal I, Luo J, Wu Y, Colditz G . Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer. Cancer Res. 2012; 72(17):4574-86. PMC: 3899801. DOI: 10.1158/0008-5472.CAN-12-0636. View

15.

Trauner M, Fuchs C . Novel therapeutic targets for cholestatic and fatty liver disease. Gut. 2021; 71(1):194-209. PMC: 8666813. DOI: 10.1136/gutjnl-2021-324305. View

16.

Cline M, Smoot M, Cerami E, Kuchinsky A, Landys N, Workman C . Integration of biological networks and gene expression data using Cytoscape. Nat Protoc. 2007; 2(10):2366-82. PMC: 3685583. DOI: 10.1038/nprot.2007.324. View

17.

Sun W, Qiu G, Zou Y, Cai Z, Wang P, Lin X . Knockdown of TMEM45A inhibits the proliferation, migration and invasion of glioma cells. Int J Clin Exp Pathol. 2016; 8(10):12657-67. PMC: 4680400. View

18.

Crawford D, Ilic Z, Guest I, Milne G, Hayes J, Sell S . Characterization of liver injury, oval cell proliferation and cholangiocarcinogenesis in glutathione S-transferase A3 knockout mice. Carcinogenesis. 2017; 38(7):717-727. PMC: 5862260. DOI: 10.1093/carcin/bgx048. View

19.

Sayers E, Barrett T, Benson D, Bryant S, Canese K, Chetvernin V . Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 2008; 37(Database issue):D5-15. PMC: 2686545. DOI: 10.1093/nar/gkn741. View

20.

Guo J, Chen L, Luo N, Yang W, Qu X, Cheng Z . Inhibition of TMEM45A suppresses proliferation, induces cell cycle arrest and reduces cell invasion in human ovarian cancer cells. Oncol Rep. 2015; 33(6):3124-30. DOI: 10.3892/or.2015.3902. View